Vaxcyte, Inc. (PCVX)
NASDAQ · Healthcare
Vaxcyte, Inc. Shareholder Equity 2020–2025
Vaxcyte, Inc. annual shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Vaxcyte, Inc. shareholder equity as of December 31, 2025: 2.69B, a 18.76% decrease year-over-year.
- Vaxcyte, Inc. shareholder equity for 2025 were 2.69B, a 18.76% decrease from 2024.
- Vaxcyte, Inc. shareholder equity for 2024 were 3.31B, a 166.50% increase from 2023.
- Vaxcyte, Inc. shareholder equity for 2023 were 1.24B, a 30.08% increase from 2022.
- Vaxcyte, Inc. shareholder equity for 2022 were 953.6M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Vaxcyte, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $2,686 |
| 2024 | $3,306 |
| 2023 | $1,240 |
| 2022 | $954 |
| 2021 | $284 |
| 2020 | $346 |
Vaxcyte, Inc. Shareholder Equity — FAQ
Vaxcyte, Inc. (PCVX) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see PCVX's shareholder equity history?
The chart and table above show Vaxcyte, Inc.'s shareholder equity by year and by quarter, including the growth rate.